An artificially constructed radiation-responsive promoter is activated by doxorubicin

R. Ogawa*, A. Morii, A. Watanabe, Z. G. Cui, G. Kagiya, N. Doi, Q. L. Zhao, L. B. Feril

*この論文の責任著者

研究成果: ジャーナルへの寄稿学術論文査読

4 被引用数 (Scopus)

抄録

We previously developed an artificially constructed promoter that was activated in response to X-ray irradiation in LNCap, a prostate cancer cell line. Anticancer drugs were examined to see whether some of them could stimulate the activity of the promoter. It was found that doxorubicin (Dox) treatment to LNCap transfected with a gene cassette of the luciferase gene under control of the promoter-enhanced luciferase activity in a dose-dependent manner, indicating that the promoter could be controlled by Dox. When the luciferase gene was replaced with the fcy::fur gene whose product facilitates conversion of 5-fluorocytosine into 5-fluorouracil that is highly toxic, Dox stimulated the expression of the gene product, resulting in facilitation of cell killing effect in the presence of 5-fluorocytosine. These results suggest that therapeutic gene expression controlled with an anticancer drug may lead to a more effective cancer therapy with less hazardous side effects.

本文言語英語
ページ(範囲)345-351
ページ数7
ジャーナルCancer Gene Therapy
19
5
DOI
出版ステータス出版済み - 2012/05

ASJC Scopus 主題領域

  • 分子医療
  • 分子生物学
  • 癌研究

フィンガープリント

「An artificially constructed radiation-responsive promoter is activated by doxorubicin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル